Global Ortho And Osteobiologics Market Set To Grow To $6.1bn By 2023

03 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Ortho and Osteobiologics Market 2018-2028: Viscosupplementation Products, Demineralized Bone Matrices, Synthetic Orthobiologics, Bone Morphogenic Protein, Allografts, Plasma-rich Protein, Bone Marrow Aspirate, Osteoarthritis, Spinal Fusion, Fracture, Soft Tissue Injury, Hospitals, Clinics, Research and Academic Institutes
The Ortho and Osteobiologics industry has evolved tremendously in recent years with an array of novel technological development being designated to treat orthopaedic disorders. The regulatory authorities such as the U.S. FDA and EMA are streamlining the regulatory process and approving different advanced devices. There is a huge market potential in the developing countries of Asia-Pacific and LAMEA regions, as the healthcare infrastructure, awareness, and affordability have increased in these regions.

The lead analyst of the report commented “Continuous technological innovations in ortho and osteobiologics industry is set to drive the market at an exponential rate. The emergence of natural biomaterials-based ortho and osteobiologics has revolutionized the ortho and osteobiologics industry as these have several advantages compared to synthetic biomaterials.

Competitive rivalry is intense in the Ortho and Osteobiologics market owing to high number of competitors of nearly equal market size and share. Companies competing in the Ortho and Osteobiologics market are continuously putting efforts to gain market share through novel product launches & product approvals owing to the large scope of product differentiation.”

Leading companies featured in the report include Johnson & Johnson (DePuy Synthes), Medtronic PLC, Colson Associates, Inc. (OsteoMed LLC), Arthrex, Inc, Stryker Corporation, Zimmer Biomet Holdings, Inc. (Zimmer Biomet), Smith & Nephew plc, Orthofix International N.V., Skye Osteobiologics Inc., BioVentus.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever